Ann: Factor Therapeutics Appoints Transaction Advisor, page-40

Am I missing something here or is it just subtleties. The first section of this announcement says “successful phase 2 readout” whilst the last para says awaiting Phase 2 readout. I reckon we are looking pretty damn good. Here’s what investopedia says about Phase 2 readouts.

“Phase 2 trials are considered successful when analysis of the data from enrolled participants reveals that the experimental drug works in treating the disease or indication. Patients who have received the experimental drug should have better clinical outcomes on a statistically significant basis than those who received the placebo or the alternative drug. If Phase 2 trials are successful, the drug proceeds to Phase 3 studies.

Phase 2 studies only commence if Phase 1 studies do not reveal unduly high toxicity or other safety risks of the experimental drug. While up to a third of drugs in Phase 1 studies do not progress to the Phase 2 stage because they are not safe enough, the odds of a drug progressing from Phase 2 to Phase 3 trials are even lower, about 32 percent to 39 percent.

Because of the relatively low rate of success at the Phase 2 stage, market reaction to a successful Phase 2 outcome is generally rewarded with significant stock price appreciation for the company developing the drug. The degree of stock appreciation depends on a number of factors including: the prevailing environment for equities in general and healthcare stocks in particular, the disease or indication that the drug aims to treat, the strength of the Phase 2 results, and price movement in the stock prior to the release of Phase 2 results.”


There’s more significant stock price appreciation coming our way in my book! Dyor

Read more: Phase 2 Definition | Investopedia https://www.investopedia.com/terms/p/phase-2.asp#ixzz5UKPkge3f
Follow us: Investopedia on Facebook